seletalisib

Seletalisib is an orally bioavailable small molecule that acts as a potent and selective inhibitor of Phosphatidylinositol 3-kinase delta (PI3Kδ). It was developed by UCB for the treatment of immune and inflammatory diseases, including primary Sjogren's syndrome, psoriasis, and immunodeficiency disorders. Seletalisib blocks human T-cell production of several cytokines from activated T-cells and inhibits B-cell proliferation and cytokine release. In preclinical studies, it demonstrated functional selectivity towards PI3Kδ-expressing cells such as lymphocytes. Clinical trials showed that seletalisib was well tolerated at tested doses with no major safety concerns identified[1][2][3][5][6].

Other names

seletalisib